Guardant Health, Inc.
NASDAQ:GH · NASDAQ Global Select
+$2.67 today
Vol 3.16M · Avg 2.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
419.2%
avg -85.3%
ROIC
-25.0%
avg -25.7%
ROA
-20.7%
avg -23.3%
Analysis
ROE is currently the strongest return metric at 419.2% versus its period average of -85.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Bell | Chief Financial Officer | $976,029.00 | — | 57 | $49,548.00 | 0.04% |
John G. Saia | Chief Legal Officer & Corporate Secretary | $914,430.00 | — | 53 | $0.00 | <0.01% |
Darya Chudova | Chief Technology Officer | $908,421.00 | — | 52 | $74,402.00 | 0.06% |
Craig Eagle | Chief Medical Officer | $844,862.00 | — | 59 | $77,780.00 | 0.06% |
Terilyn Juarez Monroe | Chief People Officer | $787,541.00 | — | 59 | $20,990.00 | 0.02% |
AmirAli Talasaz | Co-CEO & Director | $13,518.00 | — | 46 | $2.02M | 1.52% |
Helmy Eltoukhy | Co-Founder, Co-CEO & Chairman | $13,423.00 | — | 47 | $2.06M | 1.56% |
Zarak Khurshid | Vice President of Investor Relations | — | — | — | — | — |
Andy Ament | Senior Vice President of Operations | — | — | — | — | — |
Gulshan Shaver | Senior Vice President of Legal Affairs & Chief Compliance Officer | — | — | — | — | — |
Kumud Kalia | Chief Information Officer | — | — | 60 | $41,728.00 | 0.03% |
Stephen Murphy | Senior Vice President of Screening Marketing | — | — | — | — | — |
Jennifer Higgins | Senior Vice President of Public Affairs | — | — | — | — | — |
Noam Krantz | Senior Vice President of Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
44
$52.54M
Net Sentiment
$52.54M
Net selling
Most Active
Talasaz AmirAli
13 transactions
1–10 of 44
Analysis
Insiders reported 0 buys worth $0.00 and 44 sells worth $52.54M over the last 12 months. That adds up to net selling of $52.54M. Talasaz AmirAli was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +79.2% | +27.9% (10yr)8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | N/A | N/A8 analysts |
Analysis
Recent growth has been strongest in Revenue at +79.2% over three years. Forward estimates point to Revenue at +27.9% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Viatris Inc.
NASDAQ:VTRS
$17.90B
Ascendis Pharma A/S
NASDAQ:ASND
$14.34B
Solventum Corporation
NYSE:SOLV
$13.07B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$12.98B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.25B
ICON Public Limited Company
NASDAQ:ICLR
$11.18B
Revvity, Inc.
NYSE:RVTY
$11.15B
Encompass Health Corporation
NYSE:EHC
$9.72B
Qiagen N.V.
NYSE:QGEN
$7.62B
Who manages GH?
Guardant Health, Inc. (GH) lists 14 active executives. The top listed executive is John G. Saia, Chief Legal Officer & Corporate Secretary.
Are GH insiders buying or selling?
Recent insider activity shows net selling of $64.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.